Drug intelligence / Profile preview

ARNV-F2

Development stage: Preclinical
Lead developer: Arnav Biotech
Modality: Peptides
Administration: Intranasal

Overview

ARNV-F2 is a peptide-based fusion inhibitor being developed by Arnav Biotech for the treatment and prevention of respiratory syncytial virus (RSV) infection in infants, children, and the elderly. Exclusively licensed from Alabama State University, the drug candidate is derived from the RSV fusion (F) protein precursor F0 (specifically the RF-482 peptide sequence). ARNV-F2 acts by binding to the RSV fusion glycoprotein, thereby blocking viral membrane fusion and entry into host cells. The program is currently in pre-clinical and IND-enabling development.

Targets

RSV F (Respiratory syncytial virus fusion protein)

Beyond the preview

Go deeper on ARNV-F2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ARNV-F2.

Explore the full profile